Replies to post #71042 on Biotech Values

[DewDiligence]

The way its structured Biomarin pays but its on la jolla's books, so its not a P&L hit for bmrn.

The up-front payment and the additional payment to opt in will run through BMRN’s P&L statement; the only expense BMRN keeps off its own P&L is the cost of running the clinical trials.